ANIK — Stock Film
STOCK FILMSCENE 1/11ANIK · $21.78
Stock Expert AI presents
ANIK
Anika Therapeutics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Anika Therapeutics, Inc. A quick introduction.

On the stock market since 1993, it operates in the world of health and science. It has 288 employees. Now — the numbers.

on the stock market since 1993
288 employees
$204.8M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.1.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

WHERE DOES THE MONEY COME FROM?
85%Joint Preservation and Restoration
Joint Preservation and Restoration 85%Non-Orthopedic 15%
85% of all revenue comes from a single line: Joint Preservation and Restoration.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

In the vault right now:
$0
DEBT: $26.2M
At this pace, that money lasts about 5.3 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
77
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
91
very strong

Debt is low and cash is strong; the finances stand solid.

VALUATION
65
strong

Clearly above the class average — a step short of the very top.

GROWTH
62
average

There is growth, but not at top-of-the-class tempo.

PRICE MOMENTUM
91
very strong

The stock has been running stronger than the market lately.

No real weak spot in any of the five subjects — a balanced report card.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking8/10
Heavy investment in the future10/10
Few are betting against it10/10
WEAK SPOTS
Growth has stalled2/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 52% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/2
Strong cash, light debt

There is $57.5M in the vault; even if every debt were paid off, $31.2M would remain.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 36 buys and 17 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
Running at a loss

A loss of $10.9M against $112.8M in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
Growth has stalled

The sales tempo runs behind the sector. Council score: 2/10. The high “Growth” grade on the report card comes from profit power instead.

FINALE · THE GRADE
A
0 / 100 · MoonshotScore

On our five-subject report card, ANIK sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: ANIK is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 22, 2026 · stockexpertai.com · Stock Film